To substantiate the translational potentials of USP7-TAZ axis as novel therapeutic targets, we exploited a HNSCC PDX and P5091 which had been verified as a potent inhibitor of USP7 in preclinical cancer models (Fig. 7A). The gene discussed is WWTR1; the disease is cancer.